What's the recommended frequency for lurbinectedin's side effect surveillance?

How often should side effects be monitored for lurbinectedin?

The provided information doesn’t include any dosing, trial protocol, or post-marketing safety-monitoring schedule for lurbinectedin, so there’s no basis here to state a recommended surveillance frequency.

Where the “recommended frequency” usually comes from (and what to check)

When labeling or a study protocol specifies side-effect surveillance frequency, it typically comes from one of these documents:
- The drug’s prescribing information (package insert) in the “Warnings and Precautions” and “Adverse Reactions”/safety monitoring sections
- The clinical trial protocol (e.g., visit schedule for AE/SAE collection and lab monitoring)
- A risk management plan (RMP) or pharmacovigilance guidance, if applicable

If you share the label excerpt, I can pinpoint the frequency

If you paste the relevant section from the lurbinectedin label (or tell me the exact document/source you’re using, like “US prescribing information” vs “EMA SmPC”), I can extract the stated surveillance cadence verbatim and help interpret it.

Sources

No sources were provided in the prompt to cite.